WO1997018814A1 - Pharmaceutical formulations - Google Patents
Pharmaceutical formulations Download PDFInfo
- Publication number
- WO1997018814A1 WO1997018814A1 PCT/EP1996/005020 EP9605020W WO9718814A1 WO 1997018814 A1 WO1997018814 A1 WO 1997018814A1 EP 9605020 W EP9605020 W EP 9605020W WO 9718814 A1 WO9718814 A1 WO 9718814A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formulation
- molecular weight
- polyethylene oxide
- range
- low molecular
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
Definitions
- This invention relates to controlled-release oral pharmaceutical formulations
- Controlled-release oral pharmaceutical formulations are known Their purpose is to modify the rate of drug release, for example to produce a constant rate of release of a drug into the gastrointestinal tract of a patient, or to delay the release of a drug into the gastrointestinal tract of a patient (see 'Sustained and Controlled Release Drug Delivery Systems', pp 3-6, edited by J R Robinson, published by Marcel Dekker Inc)
- US Patent N° 4,765,989 discloses an osmotic delivery device for delivering inter alia nifedipi ⁇ e or doxazosin It has a perforated semipermeable wall enclosing a drug composition which includes an osmopolymer, and a pusher composition containing a second osmopolymer
- a drug composition which includes an osmopolymer
- a pusher composition containing a second osmopolymer The performance of this prior art device is satisfactory, but it has the disadvantage that it is very complicated, leading to high manufacturing costs
- UK Patent Application 2,123,291 discloses a sustained release formulation of suloctidil which is a two-part tablet a first part is a prompt-release portion and a second part is a slow-release portion, which must contain a surface-active agent to promote bio-erosion
- US Patent N° 5,393,765 discloses an erodibie pharmaceutical composition providing a zero order controlled release profile, comprising low viscosity hydroxypropylmethyl cellulose
- a controlled-release pharmaceutical formulation for oral administration consisting essentially of an active drug compound low molecular weight polyethylene oxide, hydroxypropylmethyl cellulose tabletting excipients and optionally one or more enteric polymers
- formulations of the present invention may also be administered buccally (i e placed behind the top lip and allowed to dissolve) and the term includes such formulations "Consisting essentially of means that at least 95% by weight of the formulation is made up of the listed components. At least 99% by weight of uncoated formulations, and the cores of coated formulations, are preferably made up of the listed components.
- Polymerized ethylene oxide having a number average molecular weight less than 100,000 is sometimes referred to as "polyethylene glycol".
- polyethylene glycol Polyethylene glycol
- low molecular weight polyethylene oxide is used to refer to polymerized ethylene oxide in the number average molecular weight range of interest, namely 15,000 to 750,000.
- Tabletting excipients making up formulations according to the invention may be conven ⁇ tional tabletting excipients, for example dibasic calcium phosphate, lactose and magnesium stearate.
- the first class is weakly basic compounds. Examples of this class include dipyridamole, noscapine, papaverine, doxazosin, sildenafil and prazosin. Doxazosin and its pharmaceutically acceptable salts are of particular interest.
- the second class are compounds having high solubility in aqueous media.
- this class include salbutamol, metoprolol, propanolol, aminophylline, isosorbide mono- and dinitrate, glyceryl trinitrate, verapamil, captopril, diltiazem, morphine, chlorpheni- ramine, promethazine, eletriptan, darifenacin and fluconazole.
- the third class are compounds having low solubility in aqueous media.
- Examples of this class include nifedipine, griseofulvin, carbamazepine, felodipine, nimodipine and megestrol.
- solubility in aqueous media and “low solubility in aqueous media” will be understood by those skilled in the art. However, the former may be defined as a solubility
- Formulations according to the invention have the advantage that they produce a constant rate of release of drugs that are weakly basic and/or have a high solubility in aqueous media in in vitro models of the gastrointestinal tract, and so are expected to produce a constant rate of release of the drug in the gastrointestinal tract of a patient.
- the formulations of the invention have the advantage that they produce a delayed or pulsed release of the drug.
- the formulations are very simple and so can be manufactured at a compara ⁇ tively low cost.
- the hydroxypropylmethyl cellulose has a number average molecular weight in the range 80,000-250,000.
- the hydroxypropylmethyl cellulose has a degree of methyl substitution in the range 19-30 %.
- the hydroxypropylmethyl cellulose has a degree of hydroxy substitution in the range 4-12 %.
- a number of hydroxypropylme- thyl cellulose polymers are available commercially under the brand name Methocel®, and some of those suitable for use in formulations according to the invention are given in the table below:
- Methocel® K4M has characteristics of particular interest.
- the low molecular weight polyethylene oxide has a number average molecular weight in the range 20,000 to 500,000, more preferably 100,000-300,000.
- Polyethylene oxide with a number average molecular weight above 100,000 is a powder, which makes it easier to handle than lower molecular weight polyethylene oxide, which has a lower melting point.
- polyethylene oxide with a number average molecular weight of 6000 has a melting point of 60-63°C It will be apparent to those skilled in the art that the polyethylene oxide may consist of molecules of different chain lengths, but that the average chain length gives a molecular weight in the range stated. The same applies to the hydroxypropylmethyl cellulose.
- Formulations according to the invention may contain an enteric polymer admixed with the other components of the formulation.
- formulations according to the invention are preferably provided with a coating of an enteric polymer.
- Enteric polymers that may be mentioned are phthalate derivatives (including cellulose acetate phthalate, polyvinyiacetate phthalate and hydroxypropylmethyl cellulose phthalate), polyacrylic acid derivatives (including methacrylic acid copolymer), and vinyl acetate and crotonic acid copolymers. Methacrylic acid copolymer is of particular interest.
- the formulation contains up to 50% by weight of active drug compound, for example 1-20%.
- formulations of the invention contain 5-30% by weight of low molecular weight polyethylene oxide, for example 8-10%.
- the formulations of the invention contain 10-60% by weight of hydroxypropyl- methyl cellulose, for example 25-35%.
- Formulations having enteric polymer admixed with the other components of the formula ⁇ tion preferably have 10-40% by weight of admixed enteric polymer, for example 25-35%.
- the mass ratio of low molecular weight polyethylene oxide:hydroxypropylmethyl cellulose is in the range 2:1- 1 :5.
- the mass ratio of (low molecular weight polyethylene ox- ide+hydroxypropylmethyl cellulose):admixed enteric polymer is in the range 1 :2-6: 1 , more preferably 1 :2-2:1.
- the enteric coating (where present) makes up 2-15% by weight of the formulation, more preferably 5-10% by weight of the formulation.
- the use of low molecular weight polyethylene oxide in an oral controlled-release pharmaceutical formulation having a hydroxypropylmethyl cellulose matrix, to enhance the erosion of the matrix after a predetermined period of time following administration of the formulation to a patient
- the predetermined period of time is 6 hours In this way, a constant rate of drug release can be achieved in the gastrointestinal tract of a patient despite the varying conditions which exist along its length
- a process for the production of a pharmaceutical formulation as defined in claim 1 which comprises mixing an active drug compound, low molecular weight polyethylene oxide, hydroxypropylmethyl cellulose, tabletting excipients, and optionally one or more enteric polymers, followed by pressing into tablets
- formulations according to the present invention may be measured in a model of the gastrointestinal tract such as Apparatus 1 of USP 22, page
- Figure 1 shows the percentage of drug compound released v time from formulations according to the invention [as prepared in Examples 1 (a) and 1 (b)] in comparison with a control [as prepared in Example 6] using simple dissolution testing
- Figure 2 shows the percentage of drug compound released v time from a formulation according to the invention [as prepared in Example 2(a)] using dissolution testing with first an acidic and then a neutral dissolution medium
- Methacrylic acid copolymer type C a 6 500
- Example 5 Sustained release formulations of fluconazole (suitable for buccal administration.
- Example 1 The tablets of Examples 1 (a), 1 (b) and 6 were dissolved using Apparatus 1 of USP 22, page 1578, Method 1 (baskets)
- the dissolution fluid was 900ml of water at 37°C
- the rotation speed of the baskets was 100 rpm
- the drug compound released was detected by UV spectroscopy at a wavelength of 246 nm
- the percentage of drug compound released v time for each tablet type is shown in Figure 1
- Example 2(a) The tablets of Example 2(a) were dissolved using Apparatus 1 of USP 22, page 1578, Method 1 (baskets)
- the rotation speed of the baskets was 200 rpm, and the drug compound released was detected by UV spectros- copy at a wavelength of 246 nm
- the percentage of drug compound released v time is shown in Figure 2
Abstract
Description
Claims
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR9611626A BR9611626A (en) | 1995-11-21 | 1996-11-11 | Pharmaceutical formulations |
HU9903734A HUP9903734A3 (en) | 1995-11-21 | 1996-11-11 | Controlled-release pharmaceutical formulations for oral administration and method for preparing this |
AU75721/96A AU709560B2 (en) | 1995-11-21 | 1996-11-11 | Pharmaceutical formulations |
KR1019980703777A KR19990071505A (en) | 1995-11-21 | 1996-11-11 | Pharmaceutical preparations |
EP96938215A EP0862437A1 (en) | 1995-11-21 | 1996-11-11 | Pharmaceutical formulations |
JP9519364A JPH10513481A (en) | 1995-11-21 | 1996-11-11 | Pharmaceutical preparations |
PL96326981A PL326981A1 (en) | 1995-11-21 | 1996-11-11 | Pharmaceutic preparations |
NZ322053A NZ322053A (en) | 1995-11-21 | 1996-11-11 | Controlled release pharmaceutical formulation comprising an active, a low MW polyethylene oxide, HPMC and one or more enteric polymers |
SK630-98A SK63098A3 (en) | 1995-11-21 | 1996-11-11 | Controlled-release pharmaceutical formulation, process for its preparation and use of polyethyleneoxide |
IS4706A IS4706A (en) | 1995-11-21 | 1998-03-31 | pharmaceutical compositions |
BG102438A BG102438A (en) | 1995-11-21 | 1998-05-08 | Medicamentous form |
NO982302A NO982302L (en) | 1995-11-21 | 1998-05-20 | Pharmaceutical composition |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9523752.5 | 1995-11-21 | ||
GBGB9523752.5A GB9523752D0 (en) | 1995-11-21 | 1995-11-21 | Pharmaceutical formulations |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1997018814A1 true WO1997018814A1 (en) | 1997-05-29 |
Family
ID=10784188
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1996/005020 WO1997018814A1 (en) | 1995-11-21 | 1996-11-11 | Pharmaceutical formulations |
Country Status (29)
Country | Link |
---|---|
EP (1) | EP0862437A1 (en) |
JP (1) | JPH10513481A (en) |
KR (1) | KR19990071505A (en) |
CN (1) | CN1215993A (en) |
AP (1) | AP718A (en) |
AR (1) | AR004335A1 (en) |
AU (1) | AU709560B2 (en) |
BG (1) | BG102438A (en) |
BR (1) | BR9611626A (en) |
CA (1) | CA2232715A1 (en) |
CO (1) | CO4480020A1 (en) |
CZ (1) | CZ155498A3 (en) |
GB (1) | GB9523752D0 (en) |
HR (1) | HRP960554A2 (en) |
HU (1) | HUP9903734A3 (en) |
IS (1) | IS4706A (en) |
MA (1) | MA26410A1 (en) |
MX (1) | MX9804008A (en) |
NO (1) | NO982302L (en) |
NZ (1) | NZ322053A (en) |
OA (1) | OA10687A (en) |
PE (1) | PE22898A1 (en) |
PL (1) | PL326981A1 (en) |
SK (1) | SK63098A3 (en) |
TN (1) | TNSN96141A1 (en) |
TR (1) | TR199800902T2 (en) |
WO (1) | WO1997018814A1 (en) |
YU (1) | YU62096A (en) |
ZA (1) | ZA969722B (en) |
Cited By (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999030697A2 (en) * | 1997-12-16 | 1999-06-24 | Pfizer Products Inc. | Combination effective for the treatment of impotence |
EP0960621A2 (en) * | 1998-05-15 | 1999-12-01 | Pfizer Inc. | Pharmaceutical formulations comprising sildenafil |
EP0974343A1 (en) * | 1998-07-22 | 2000-01-26 | Pharma Pass LLC | Metoprolol composition and processes for manufacturing the same |
EP0987020A1 (en) * | 1998-09-04 | 2000-03-22 | Pharma Pass LLC | Metoprolol composition and processes for manufacturing the same |
WO2000024383A1 (en) * | 1998-10-23 | 2000-05-04 | Pfizer Research And Development Company, N.V./S.A. | Controlled-release pharmaceutical formulations containing a cgmp pde-5 inhibitor |
US6475521B1 (en) | 1998-03-19 | 2002-11-05 | Bristol-Myers Squibb Co. | Biphasic controlled release delivery system for high solubility pharmaceuticals and method |
EP1293196A2 (en) * | 2001-09-14 | 2003-03-19 | Pharma Pass II LLC | Pharmaceutical composition comprising doxazosin |
US6723340B2 (en) | 2001-10-25 | 2004-04-20 | Depomed, Inc. | Optimal polymer mixtures for gastric retentive tablets |
WO2005037247A2 (en) * | 2003-10-17 | 2005-04-28 | Ranbaxy Laboratories Limited | Oral matrix formulations of doxazosin |
WO2005107702A2 (en) * | 2004-05-11 | 2005-11-17 | Glenmark Pharmaceuticals Limited | Sustained release, mucoadhesive vaginal pharmaceutical compositions |
JP2006298945A (en) * | 1998-10-14 | 2006-11-02 | Novartis Ag | Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent |
WO2010071320A2 (en) | 2008-12-17 | 2010-06-24 | 동아제약 주식회사 | Controlled-release composition for producing sustained-release preparation containing udenafil |
US7759368B2 (en) * | 2004-05-28 | 2010-07-20 | Hanmi Pharm. Co., Ltd | Sustained release composition for oral administration of niacin |
WO2010123930A2 (en) | 2009-04-20 | 2010-10-28 | Elcelyx Therapeutics, Inc. | Chemosensory receptor ligand-based therapies |
US20110150989A1 (en) * | 2009-12-22 | 2011-06-23 | Mallinkckrodt Inc. | Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans |
WO2012006398A2 (en) | 2010-07-09 | 2012-01-12 | Bhv Pharma, Inc. | Combination immediate/delayed release delivery system for short half-life pharmaceuticals including remogliflozin |
US8329217B2 (en) | 2001-11-06 | 2012-12-11 | Osmotica Kereskedelmi Es Szolgaltato Kft | Dual controlled release dosage form |
US8333992B2 (en) | 2001-10-25 | 2012-12-18 | Depomed, Inc. | Gastric retained gabapentin dosage form |
US8372432B2 (en) | 2008-03-11 | 2013-02-12 | Depomed, Inc. | Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic |
US8377453B2 (en) | 2008-03-11 | 2013-02-19 | Depomed, Inc. | Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic |
US8440232B2 (en) | 2001-10-25 | 2013-05-14 | Depomed, Inc. | Methods of treatment using a gastric retained gabapentin dosage |
WO2013158928A2 (en) | 2012-04-18 | 2013-10-24 | Elcelyx Therapeutics, Inc. | Chemosensory receptor ligand-based therapies |
US8592481B2 (en) | 2005-12-29 | 2013-11-26 | Depomed, Inc. | Gastric retentive gabapentin dosage forms and methods for using same |
US8741885B1 (en) | 2011-05-17 | 2014-06-03 | Mallinckrodt Llc | Gastric retentive extended release pharmaceutical compositions |
US8821930B2 (en) | 2006-04-26 | 2014-09-02 | Supernus Pharmaceuticals, Inc. | Modified release preparations containing oxcarbazepine and derivatives thereof |
US8828953B2 (en) | 2009-04-20 | 2014-09-09 | NaZura BioHealth, Inc. | Chemosensory receptor ligand-based therapies |
US8858963B1 (en) | 2011-05-17 | 2014-10-14 | Mallinckrodt Llc | Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia |
US9050335B1 (en) | 2011-05-17 | 2015-06-09 | Mallinckrodt Llc | Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia |
US9198861B2 (en) | 2009-12-22 | 2015-12-01 | Mallinckrodt Llc | Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans |
US9321791B2 (en) | 2002-08-21 | 2016-04-26 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
US9415016B2 (en) | 2008-04-03 | 2016-08-16 | Boehringer Ingelheim International Gmbh | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
US9421179B2 (en) | 2011-12-02 | 2016-08-23 | Synchroneuron, Inc. | Acamprosate formulations, methods of using the same, and combinations comprising the same |
US9457029B2 (en) | 2009-11-27 | 2016-10-04 | Boehringer Ingelheim International Gmbh | Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin |
US9486463B2 (en) | 2010-10-19 | 2016-11-08 | Ambra Bioscience Llc | Chemosensory receptor ligand-based therapies |
US9486526B2 (en) | 2008-08-06 | 2016-11-08 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients inappropriate for metformin therapy |
US9493462B2 (en) | 2006-05-04 | 2016-11-15 | Boehringer Ingelheim International Gmbh | Polymorphs |
US9499546B2 (en) | 2004-11-05 | 2016-11-22 | Boehringer Ingelheim International Gmbh | Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines |
US9526728B2 (en) | 2014-02-28 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Medical use of a DPP-4 inhibitor |
US9526730B2 (en) | 2012-05-14 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Use of a DPP-4 inhibitor in podocytes related disorders and/or nephrotic syndrome |
US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
US9603851B2 (en) | 2010-05-05 | 2017-03-28 | Boehringer Ingelheim International Gmbh | Combination therapy |
US9713618B2 (en) | 2012-05-24 | 2017-07-25 | Boehringer Ingelheim International Gmbh | Method for modifying food intake and regulating food preference with a DPP-4 inhibitor |
US9901551B2 (en) | 2009-04-20 | 2018-02-27 | Ambra Bioscience Llc | Chemosensory receptor ligand-based therapies |
US20180185291A1 (en) | 2011-03-07 | 2018-07-05 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions |
US10076499B2 (en) | 2006-08-25 | 2018-09-18 | Purdue Pharma L.P. | Tamper resistant dosage forms |
US10080754B2 (en) | 2006-05-04 | 2018-09-25 | Boehringer Ingelheim International Gmbh | Uses of DPP IV inhibitors |
US10155000B2 (en) | 2016-06-10 | 2018-12-18 | Boehringer Ingelheim International Gmbh | Medical use of pharmaceutical combination or composition |
US10166207B2 (en) | 2013-06-05 | 2019-01-01 | Synchroneuron, Inc. | Acamprosate formulations, methods of using the same, and combinations comprising the same |
US10406172B2 (en) | 2009-02-13 | 2019-09-10 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
EP3763419A1 (en) | 2011-01-07 | 2021-01-13 | Anji Pharma (US) LLC | Chemosensory receptor ligand-based therapies |
US11033552B2 (en) | 2006-05-04 | 2021-06-15 | Boehringer Ingelheim International Gmbh | DPP IV inhibitor formulations |
US11911388B2 (en) | 2008-10-16 | 2024-02-27 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug |
US11911387B2 (en) | 2010-11-15 | 2024-02-27 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100679111B1 (en) * | 2004-11-20 | 2007-02-07 | 대우약품공업주식회사 | A sustained release tablet comprising doxazosin |
EP1919460A2 (en) * | 2005-08-22 | 2008-05-14 | Novartis AG | Pharmaceutical compositions comprising a ph-dependent drug, a ph modifier and a retarding agent |
CN100396282C (en) * | 2006-07-25 | 2008-06-25 | 山东省医药工业研究所 | Slow released doxazosin mesilate capsule and its prepn process |
CN102058555A (en) * | 2011-01-13 | 2011-05-18 | 北京汇诚瑞祥医药技术有限公司 | Doxazosin controlled release tablet |
CN102188431A (en) * | 2011-05-09 | 2011-09-21 | 浙江九旭药业有限公司 | Doxazosin mesylate sustained-release tablets and preparation method thereof |
CN105616378A (en) * | 2014-10-31 | 2016-06-01 | 康普药业股份有限公司 | Fluconazole capsule and preparation method therefor |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2123291A (en) * | 1982-07-06 | 1984-02-01 | Lepetit Spa | Suloctidil compositions |
US4765989A (en) * | 1983-05-11 | 1988-08-23 | Alza Corporation | Osmotic device for administering certain drugs |
US4837111A (en) * | 1988-03-21 | 1989-06-06 | Alza Corporation | Dosage form for dispensing drug for human therapy |
WO1992001445A1 (en) * | 1990-07-23 | 1992-02-06 | Alza Corporation | Oral osmotic device for delivering nicotine |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL92966A (en) * | 1989-01-12 | 1995-07-31 | Pfizer | Dispensing devices powered by hydrogel |
-
1995
- 1995-11-21 GB GBGB9523752.5A patent/GB9523752D0/en active Pending
-
1996
- 1996-11-11 BR BR9611626A patent/BR9611626A/en not_active Application Discontinuation
- 1996-11-11 EP EP96938215A patent/EP0862437A1/en not_active Withdrawn
- 1996-11-11 WO PCT/EP1996/005020 patent/WO1997018814A1/en not_active Application Discontinuation
- 1996-11-11 NZ NZ322053A patent/NZ322053A/en unknown
- 1996-11-11 AU AU75721/96A patent/AU709560B2/en not_active Ceased
- 1996-11-11 PL PL96326981A patent/PL326981A1/en unknown
- 1996-11-11 KR KR1019980703777A patent/KR19990071505A/en not_active Application Discontinuation
- 1996-11-11 SK SK630-98A patent/SK63098A3/en unknown
- 1996-11-11 CZ CZ981554A patent/CZ155498A3/en unknown
- 1996-11-11 TR TR1998/00902T patent/TR199800902T2/en unknown
- 1996-11-11 JP JP9519364A patent/JPH10513481A/en active Pending
- 1996-11-11 CA CA002232715A patent/CA2232715A1/en not_active Abandoned
- 1996-11-11 HU HU9903734A patent/HUP9903734A3/en unknown
- 1996-11-11 CN CN96198486A patent/CN1215993A/en active Pending
- 1996-11-20 MA MA24397A patent/MA26410A1/en unknown
- 1996-11-20 AR ARP960105252A patent/AR004335A1/en unknown
- 1996-11-20 ZA ZA9609722A patent/ZA969722B/en unknown
- 1996-11-20 TN TNTNSN96141A patent/TNSN96141A1/en unknown
- 1996-11-20 YU YU62096A patent/YU62096A/en unknown
- 1996-11-20 PE PE1996000831A patent/PE22898A1/en not_active Application Discontinuation
- 1996-11-21 CO CO96061449A patent/CO4480020A1/en unknown
- 1996-11-21 AP APAP/P/1996/000883A patent/AP718A/en active
- 1996-11-21 HR HR9523752.5A patent/HRP960554A2/en not_active Application Discontinuation
-
1998
- 1998-03-31 IS IS4706A patent/IS4706A/en unknown
- 1998-05-08 BG BG102438A patent/BG102438A/en unknown
- 1998-05-19 OA OA9800058A patent/OA10687A/en unknown
- 1998-05-20 MX MX9804008A patent/MX9804008A/en unknown
- 1998-05-20 NO NO982302A patent/NO982302L/en not_active Application Discontinuation
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2123291A (en) * | 1982-07-06 | 1984-02-01 | Lepetit Spa | Suloctidil compositions |
US4765989A (en) * | 1983-05-11 | 1988-08-23 | Alza Corporation | Osmotic device for administering certain drugs |
US4837111A (en) * | 1988-03-21 | 1989-06-06 | Alza Corporation | Dosage form for dispensing drug for human therapy |
WO1992001445A1 (en) * | 1990-07-23 | 1992-02-06 | Alza Corporation | Oral osmotic device for delivering nicotine |
Cited By (119)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999030697A3 (en) * | 1997-12-16 | 1999-08-26 | Pfizer Prod Inc | Combination effective for the treatment of impotence |
WO1999030697A2 (en) * | 1997-12-16 | 1999-06-24 | Pfizer Products Inc. | Combination effective for the treatment of impotence |
US6660300B1 (en) | 1998-03-19 | 2003-12-09 | Bristol-Myers Squibb Co. | Method of use of a biphasic controlled release delivery system for high solubility pharmaceuticals and method |
EP2332522A2 (en) | 1998-03-19 | 2011-06-15 | Bristol-Myers Squibb Company | Biphasic controlled release delivery system for high solubility pharmaceuticals and method |
US6475521B1 (en) | 1998-03-19 | 2002-11-05 | Bristol-Myers Squibb Co. | Biphasic controlled release delivery system for high solubility pharmaceuticals and method |
EP0960621A2 (en) * | 1998-05-15 | 1999-12-01 | Pfizer Inc. | Pharmaceutical formulations comprising sildenafil |
EP0960621A3 (en) * | 1998-05-15 | 2000-01-05 | Pfizer Inc. | Pharmaceutical formulations comprising sildenafil |
SG79255A1 (en) * | 1998-05-15 | 2001-03-20 | Pfizer | Pharmaceutical formulations |
AU753478B2 (en) * | 1998-05-15 | 2002-10-17 | Pfizer Inc. | Pharmaceutical formulations |
EP0974343A1 (en) * | 1998-07-22 | 2000-01-26 | Pharma Pass LLC | Metoprolol composition and processes for manufacturing the same |
EP0987020A1 (en) * | 1998-09-04 | 2000-03-22 | Pharma Pass LLC | Metoprolol composition and processes for manufacturing the same |
JP2006298945A (en) * | 1998-10-14 | 2006-11-02 | Novartis Ag | Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent |
BG65323B1 (en) * | 1998-10-23 | 2008-02-29 | Pfizer Research And Development Company, N.V./S.A. | Permanent-release pharmaceutical formulations containing a cgmp pde-5 inhibitor |
US6964780B1 (en) | 1998-10-23 | 2005-11-15 | Pfizer Inc. | Controlled-release pharmaceutical formulations |
WO2000024383A1 (en) * | 1998-10-23 | 2000-05-04 | Pfizer Research And Development Company, N.V./S.A. | Controlled-release pharmaceutical formulations containing a cgmp pde-5 inhibitor |
JP2002528408A (en) * | 1998-10-23 | 2002-09-03 | ファイザー・インク | Controlled release pharmaceutical formulation containing cGMPPDE-5 inhibitor |
AU756509B2 (en) * | 1998-10-23 | 2003-01-16 | Pfizer Ireland Pharmaceuticals | Controlled-release pharmaceutical formulations containing a cGMP PDE-5 inhibitor |
EP1293196A3 (en) * | 2001-09-14 | 2004-01-02 | Pharma Pass II LLC | Pharmaceutical composition comprising doxazosin |
EP1293196A2 (en) * | 2001-09-14 | 2003-03-19 | Pharma Pass II LLC | Pharmaceutical composition comprising doxazosin |
EP1446106A4 (en) * | 2001-10-25 | 2006-06-07 | Depomed Inc | Optimal polymer mixtures for gastric retentive tablets |
US8475813B2 (en) | 2001-10-25 | 2013-07-02 | Depomed, Inc. | Methods of treatment using a gastric retained gabapentin dosage |
US8529955B2 (en) | 2001-10-25 | 2013-09-10 | Depomed, Inc. | Methods of treatment using a gastric retained gabapentin dosage |
US8440232B2 (en) | 2001-10-25 | 2013-05-14 | Depomed, Inc. | Methods of treatment using a gastric retained gabapentin dosage |
US8580303B2 (en) | 2001-10-25 | 2013-11-12 | Depomed, Inc. | Gastric retained gabapentin dosage form |
US8333992B2 (en) | 2001-10-25 | 2012-12-18 | Depomed, Inc. | Gastric retained gabapentin dosage form |
US8802157B2 (en) | 2001-10-25 | 2014-08-12 | Depomed, Inc. | Methods of treatment using a gastric retained gabapentin dosage form |
US8409613B2 (en) | 2001-10-25 | 2013-04-02 | Depomed, Inc. | Gastric retained gabapentin dosage form |
EP1446106A2 (en) * | 2001-10-25 | 2004-08-18 | DepoMed, Inc. | Optimal polymer mixtures for gastric retentive tablets |
EP2260832A2 (en) | 2001-10-25 | 2010-12-15 | DepoMed, Inc. | Optimal polymer mixtures for gastric retentive tablets |
EP2260832A3 (en) * | 2001-10-25 | 2010-12-29 | DepoMed, Inc. | Optimal polymer mixtures for gastric retentive tablets |
US6723340B2 (en) | 2001-10-25 | 2004-04-20 | Depomed, Inc. | Optimal polymer mixtures for gastric retentive tablets |
US8333991B2 (en) | 2001-10-25 | 2012-12-18 | Depomed, Inc. | Gastric retained gabapentin dosage form |
US8329217B2 (en) | 2001-11-06 | 2012-12-11 | Osmotica Kereskedelmi Es Szolgaltato Kft | Dual controlled release dosage form |
US8591947B2 (en) | 2001-11-06 | 2013-11-26 | Osmotica Kereskedelmi és Szolgáltató KFT | Dual controlled release dosage form |
US9556175B2 (en) | 2002-08-21 | 2017-01-31 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and thier use as pharmaceutical compositions |
US10023574B2 (en) | 2002-08-21 | 2018-07-17 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
US9321791B2 (en) | 2002-08-21 | 2016-04-26 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
US10202383B2 (en) | 2002-08-21 | 2019-02-12 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
WO2005037247A2 (en) * | 2003-10-17 | 2005-04-28 | Ranbaxy Laboratories Limited | Oral matrix formulations of doxazosin |
WO2005037247A3 (en) * | 2003-10-17 | 2005-06-30 | Ranbaxy Lab Ltd | Oral matrix formulations of doxazosin |
WO2005107702A2 (en) * | 2004-05-11 | 2005-11-17 | Glenmark Pharmaceuticals Limited | Sustained release, mucoadhesive vaginal pharmaceutical compositions |
WO2005107702A3 (en) * | 2004-05-11 | 2006-10-05 | Glenmark Pharmaceuticals Ltd | Sustained release, mucoadhesive vaginal pharmaceutical compositions |
US7759368B2 (en) * | 2004-05-28 | 2010-07-20 | Hanmi Pharm. Co., Ltd | Sustained release composition for oral administration of niacin |
US9499546B2 (en) | 2004-11-05 | 2016-11-22 | Boehringer Ingelheim International Gmbh | Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines |
US9751855B2 (en) | 2004-11-05 | 2017-09-05 | Boehringer Ingelheim International Gmbh | Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines |
US8592481B2 (en) | 2005-12-29 | 2013-11-26 | Depomed, Inc. | Gastric retentive gabapentin dosage forms and methods for using same |
US9351975B2 (en) | 2006-04-26 | 2016-05-31 | Supernus Pharmaceuticals, Inc. | Modified release preparations containing oxcarbazepine and derivatives thereof |
US9119791B2 (en) | 2006-04-26 | 2015-09-01 | Supernus Pharmaceuticals, Inc. | Modified release preparations containing oxcarbazepine and derivatives thereof |
US11166960B2 (en) | 2006-04-26 | 2021-11-09 | Supernus Pharmaceuticals, Inc. | Modified release preparations containing oxcarbazepine and derivatives thereof |
US11896599B2 (en) | 2006-04-26 | 2024-02-13 | Supernus Pharmaceuticals, Inc. | Modified release preparations containing oxcarbazepine and derivatives thereof |
US9370525B2 (en) | 2006-04-26 | 2016-06-21 | Supernus Pharmaceuticals, Inc. | Modified release preparations containing oxcarbazepine and derivatives thereof |
US8821930B2 (en) | 2006-04-26 | 2014-09-02 | Supernus Pharmaceuticals, Inc. | Modified release preparations containing oxcarbazepine and derivatives thereof |
US10220042B2 (en) | 2006-04-26 | 2019-03-05 | Supernus Pharmaceuticals, Inc. | Modified release preparations containing oxcarbazepine and derivatives thereof |
US9855278B2 (en) | 2006-04-26 | 2018-01-02 | Supernus Pharmaceuticals, Inc. | Modified release preparations containing oxcarbazepine and derivatives thereof |
US9119792B2 (en) | 2006-04-26 | 2015-09-01 | Supernus Pharmaceuticals, Inc. | Modified release preparations containing oxcarbazepine and derivatives thereof |
US9815837B2 (en) | 2006-05-04 | 2017-11-14 | Boehringer Ingelheim International Gmbh | Polymorphs |
US10301313B2 (en) | 2006-05-04 | 2019-05-28 | Boehringer Ingelheim International Gmbh | Polymorphs |
US11919903B2 (en) | 2006-05-04 | 2024-03-05 | Boehringer Ingelheim International Gmbh | Polymorphs |
US9493462B2 (en) | 2006-05-04 | 2016-11-15 | Boehringer Ingelheim International Gmbh | Polymorphs |
US11291668B2 (en) | 2006-05-04 | 2022-04-05 | Boehringer Ingelheim International Gmbh | Uses of DPP IV inhibitors |
US10080754B2 (en) | 2006-05-04 | 2018-09-25 | Boehringer Ingelheim International Gmbh | Uses of DPP IV inhibitors |
US11033552B2 (en) | 2006-05-04 | 2021-06-15 | Boehringer Ingelheim International Gmbh | DPP IV inhibitor formulations |
US11084819B2 (en) | 2006-05-04 | 2021-08-10 | Boehringer Ingelheim International Gmbh | Polymorphs |
US11304909B2 (en) | 2006-08-25 | 2022-04-19 | Purdue Pharma L.P. | Tamper resistant dosage forms |
US11938225B2 (en) | 2006-08-25 | 2024-03-26 | Purdue Pharm L.P. | Tamper resistant dosage forms |
US11826472B2 (en) | 2006-08-25 | 2023-11-28 | Purdue Pharma L.P. | Tamper resistant dosage forms |
US11904055B2 (en) | 2006-08-25 | 2024-02-20 | Purdue Pharma L.P. | Tamper resistant dosage forms |
US11304908B2 (en) | 2006-08-25 | 2022-04-19 | Purdue Pharma L.P. | Tamper resistant dosage forms |
US10076499B2 (en) | 2006-08-25 | 2018-09-18 | Purdue Pharma L.P. | Tamper resistant dosage forms |
US11298322B2 (en) | 2006-08-25 | 2022-04-12 | Purdue Pharma L.P. | Tamper resistant dosage forms |
US10076498B2 (en) | 2006-08-25 | 2018-09-18 | Purdue Pharma L.P. | Tamper resistant dosage forms |
US8394408B2 (en) | 2008-03-11 | 2013-03-12 | Depomed, Inc. | Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic |
US8668929B2 (en) | 2008-03-11 | 2014-03-11 | Depomed, Inc. | Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic |
US8372432B2 (en) | 2008-03-11 | 2013-02-12 | Depomed, Inc. | Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic |
US8377453B2 (en) | 2008-03-11 | 2013-02-19 | Depomed, Inc. | Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic |
US10973827B2 (en) | 2008-04-03 | 2021-04-13 | Boehringer Ingelheim International Gmbh | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
US9415016B2 (en) | 2008-04-03 | 2016-08-16 | Boehringer Ingelheim International Gmbh | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
US10022379B2 (en) | 2008-04-03 | 2018-07-17 | Boehringer Ingelheim International Gmbh | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
US9486526B2 (en) | 2008-08-06 | 2016-11-08 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients inappropriate for metformin therapy |
US10034877B2 (en) | 2008-08-06 | 2018-07-31 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients inappropriate for metformin therapy |
US11911388B2 (en) | 2008-10-16 | 2024-02-27 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug |
WO2010071320A2 (en) | 2008-12-17 | 2010-06-24 | 동아제약 주식회사 | Controlled-release composition for producing sustained-release preparation containing udenafil |
RU2480240C2 (en) * | 2008-12-17 | 2013-04-27 | Донг-А Фарм.Ко., Лтд. | Controlled release composition for preparing prolonged release preparation containing udenafil |
US10406172B2 (en) | 2009-02-13 | 2019-09-10 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
US8828953B2 (en) | 2009-04-20 | 2014-09-09 | NaZura BioHealth, Inc. | Chemosensory receptor ligand-based therapies |
US9901551B2 (en) | 2009-04-20 | 2018-02-27 | Ambra Bioscience Llc | Chemosensory receptor ligand-based therapies |
WO2010123930A2 (en) | 2009-04-20 | 2010-10-28 | Elcelyx Therapeutics, Inc. | Chemosensory receptor ligand-based therapies |
US10092571B2 (en) | 2009-11-27 | 2018-10-09 | Boehringer Ingelheim International Gmbh | Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin |
US9457029B2 (en) | 2009-11-27 | 2016-10-04 | Boehringer Ingelheim International Gmbh | Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin |
US9198861B2 (en) | 2009-12-22 | 2015-12-01 | Mallinckrodt Llc | Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans |
US20110150989A1 (en) * | 2009-12-22 | 2011-06-23 | Mallinkckrodt Inc. | Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans |
US10004747B2 (en) | 2010-05-05 | 2018-06-26 | Boehringer Ingelheim International Gmbh | Combination therapy |
US9603851B2 (en) | 2010-05-05 | 2017-03-28 | Boehringer Ingelheim International Gmbh | Combination therapy |
WO2012006398A2 (en) | 2010-07-09 | 2012-01-12 | Bhv Pharma, Inc. | Combination immediate/delayed release delivery system for short half-life pharmaceuticals including remogliflozin |
US9486463B2 (en) | 2010-10-19 | 2016-11-08 | Ambra Bioscience Llc | Chemosensory receptor ligand-based therapies |
US11911387B2 (en) | 2010-11-15 | 2024-02-27 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
EP3763419A1 (en) | 2011-01-07 | 2021-01-13 | Anji Pharma (US) LLC | Chemosensory receptor ligand-based therapies |
US10596120B2 (en) | 2011-03-07 | 2020-03-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions |
US20180185291A1 (en) | 2011-03-07 | 2018-07-05 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions |
US11564886B2 (en) | 2011-03-07 | 2023-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions |
US9539328B2 (en) | 2011-05-17 | 2017-01-10 | Mallinckrodt Llc | Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia |
US8741885B1 (en) | 2011-05-17 | 2014-06-03 | Mallinckrodt Llc | Gastric retentive extended release pharmaceutical compositions |
US8858963B1 (en) | 2011-05-17 | 2014-10-14 | Mallinckrodt Llc | Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia |
US9050335B1 (en) | 2011-05-17 | 2015-06-09 | Mallinckrodt Llc | Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia |
US9433582B2 (en) | 2011-05-17 | 2016-09-06 | Mallinckrodt Llc | Gastric retentive extended release pharmaceutical compositions |
US9629837B2 (en) | 2011-05-17 | 2017-04-25 | Mallinckrodt Llc | Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia |
US9468636B2 (en) | 2011-05-17 | 2016-10-18 | Mallinckrodt Llc | Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia |
US9427420B2 (en) | 2011-12-02 | 2016-08-30 | Synchroneuron, Inc. | Acamprosate formulations, methods of using the same, and combinations comprising the same |
US9421178B2 (en) | 2011-12-02 | 2016-08-23 | Synchroneuron, Inc. | Acamprosate formulations, methods of using the same, and combinations comprising the same |
US9421179B2 (en) | 2011-12-02 | 2016-08-23 | Synchroneuron, Inc. | Acamprosate formulations, methods of using the same, and combinations comprising the same |
US10512621B2 (en) | 2011-12-02 | 2019-12-24 | Synchroneuron, Inc. | Methods of treating posttraumatic stress disorder with acamprosate salts |
US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
WO2013158928A2 (en) | 2012-04-18 | 2013-10-24 | Elcelyx Therapeutics, Inc. | Chemosensory receptor ligand-based therapies |
US9526730B2 (en) | 2012-05-14 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Use of a DPP-4 inhibitor in podocytes related disorders and/or nephrotic syndrome |
US10195203B2 (en) | 2012-05-14 | 2019-02-05 | Boehringr Ingelheim International GmbH | Use of a DPP-4 inhibitor in podocytes related disorders and/or nephrotic syndrome |
US9713618B2 (en) | 2012-05-24 | 2017-07-25 | Boehringer Ingelheim International Gmbh | Method for modifying food intake and regulating food preference with a DPP-4 inhibitor |
US10166207B2 (en) | 2013-06-05 | 2019-01-01 | Synchroneuron, Inc. | Acamprosate formulations, methods of using the same, and combinations comprising the same |
US9526728B2 (en) | 2014-02-28 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Medical use of a DPP-4 inhibitor |
US10155000B2 (en) | 2016-06-10 | 2018-12-18 | Boehringer Ingelheim International Gmbh | Medical use of pharmaceutical combination or composition |
Also Published As
Publication number | Publication date |
---|---|
AR004335A1 (en) | 1998-11-04 |
CZ155498A3 (en) | 1999-03-17 |
AP718A (en) | 1999-01-06 |
MX9804008A (en) | 1998-09-30 |
NO982302L (en) | 1998-07-17 |
CN1215993A (en) | 1999-05-05 |
KR19990071505A (en) | 1999-09-27 |
IS4706A (en) | 1998-03-31 |
BG102438A (en) | 1999-01-29 |
AU7572196A (en) | 1997-06-11 |
YU62096A (en) | 1999-03-04 |
TNSN96141A1 (en) | 2005-03-15 |
GB9523752D0 (en) | 1996-01-24 |
BR9611626A (en) | 1999-06-01 |
SK63098A3 (en) | 1999-05-07 |
JPH10513481A (en) | 1998-12-22 |
MA26410A1 (en) | 2004-12-20 |
HRP960554A2 (en) | 1998-02-28 |
EP0862437A1 (en) | 1998-09-09 |
NO982302D0 (en) | 1998-05-20 |
NZ322053A (en) | 1999-11-29 |
HUP9903734A3 (en) | 2000-04-28 |
TR199800902T2 (en) | 1998-09-21 |
ZA969722B (en) | 1998-05-20 |
AU709560B2 (en) | 1999-09-02 |
OA10687A (en) | 2002-11-27 |
HUP9903734A2 (en) | 2000-03-28 |
PL326981A1 (en) | 1998-11-09 |
AP9600883A0 (en) | 1997-01-31 |
PE22898A1 (en) | 1998-05-07 |
CA2232715A1 (en) | 1997-05-29 |
CO4480020A1 (en) | 1997-07-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU709560B2 (en) | Pharmaceutical formulations | |
AU736243B2 (en) | Film coated tablet compositions having enhanced disintegration characteristics | |
US5948440A (en) | Modified release matrix formulation of cefaclor and cephalexin | |
AU2003260336C1 (en) | Sustained release formulations comprising lamotrigine | |
NZ542303A (en) | A process for preparing sustained release tablets | |
HU218673B (en) | Controlled release pharmaceutical composition for orally administration comprising opioid analgesic and process for producing its | |
KR101858797B1 (en) | Pharmaceutical compositions comprising hydromorphone and naloxone | |
ZA200200344B (en) | Method for making granules with masked taste and instant release of the active particle. | |
JPH11505542A (en) | Triphasic pharmaceutical formulation with constant and controlled release of amorphous active ingredient for once daily dosing | |
US7163696B2 (en) | Pharmaceutical formulations | |
BG107372A (en) | Sustained-release preparations of quinolone antibiotics and method for preparation thereof | |
WO2006103551A1 (en) | Controlled release formulations of oxycodone | |
JP2003508420A (en) | Controlled release oral dose suitable for oral administration | |
JP2002536318A (en) | pH-independent extended release pharmaceutical composition | |
WO2011064797A2 (en) | Controlled release pharmaceutical compositions of galantamine | |
JP5826456B2 (en) | Controlled release formulation comprising an uncoated discrete unit and an extended release matrix | |
WO2009087663A2 (en) | Oral controlled release coated tablet | |
AU2003267216A1 (en) | Mannitol formulation for integrin receptor antagonist | |
EP1434570B1 (en) | Pharmaceutical formulations for the controlled release of 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline | |
JPH04273816A (en) | Pulse-releasing nucleated tablet | |
US20080206338A1 (en) | Controlled release formulations of an alpha-adrenergic receptor antagonist | |
WO2008050188A2 (en) | Sustained release pharmaceutical compositions of alfuzosin and process for preparation thereof | |
GB2334212A (en) | Modified release matrix formulation for cefaclor and cephalexin | |
JP2707023C (en) | ||
WO2007069061A2 (en) | Controlled release compositions containing zolpidem |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 96198486.4 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU BG BR BY CA CN CZ HU IL IS JP KR KZ LK LV MX NO NZ PL RO RU SG SI SK TR UA US UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 322053 Country of ref document: NZ |
|
ENP | Entry into the national phase |
Ref document number: 2232715 Country of ref document: CA Ref document number: 2232715 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1996938215 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1199800402 Country of ref document: VN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 63098 Country of ref document: SK |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/1998/004008 Country of ref document: MX Ref document number: PV1998-1554 Country of ref document: CZ Ref document number: 1019980703777 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998/00902 Country of ref document: TR |
|
WWP | Wipo information: published in national office |
Ref document number: 1996938215 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: PV1998-1554 Country of ref document: CZ |
|
WWP | Wipo information: published in national office |
Ref document number: 1019980703777 Country of ref document: KR |
|
WWR | Wipo information: refused in national office |
Ref document number: PV1998-1554 Country of ref document: CZ |
|
WWR | Wipo information: refused in national office |
Ref document number: 1019980703777 Country of ref document: KR |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1996938215 Country of ref document: EP |